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Abstract
Backgrounds: Remifentanil has been reported to cause post-anesthetic shivering (PAS). Higher doses of
remifentanil reportedly induce more intense PAS. Tramadol, a synthetic opioid that acts at multiple sites, is
considered to be an effective treatment for PAS, but the evidence for its therapeutic benefit after remifentanil
anesthesia is limited. We investigated the effect of tramadol on the incidence of PAS after remifentanil anesthesia.
Methods: Sixty-three patients who had undergone upper abdominal surgery under general anesthesia were
studied retrospectively. Tramadol was administered at induction of anesthesia. The patients were divided into four
groups: HT(+), high dose remifentanil (1–1.5 μg/kg/min) with tramadol; HT(−), high dose remifentanil without
tramadol; LT(+), low dose remifentanil (0.15–0.25 μg/kg/min) with tramadol; and LT(−), low dose remifentanil
without tramadol. We recorded perioperative changes in nasopharyngeal temperature and episodes of PAS on
emergence from anesthesia.
Results: The incidences of PAS in both tramadol treatment groups were significantly lower than the groups that
did not receive tramadol. Nasopharyngeal temperature after surgery fell significantly more from baseline in the
tramadol treatment groups compared with the non-treatment groups.
Conclusion: Tramadol administered at induction of anesthesia appears to suppress PAS following remifentanil
anesthesia.
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Background
Remifentanil is an ultra-short acting opioid that contrib-
utes to rapid recovery after anesthesia [1]. It has, however,
been reported that remifentanil increases the risk of post-
anesthetic shivering (PAS) after abrupt withdrawal [2–6].
Moreover, it has also been reported that withdrawal from
a high dose of remifentanil induces more intense PAS
compared with a low dose [7]. Tramadol, a synthetic opi-
oid that acts at multiple sites, is often used to treat PAS
[8–16]; however, the evidence for its therapeutic benefit
after remifentanil anesthesia is limited. We investigated
the effect of tramadol on the incidence of PAS after high-
dose (1–1.5 μg/kg/min) or low-dose (0.15–0.25 μg/kg/
min) remifentanil anesthesia.
Methods
Conduct of the study was approved by our institutional
ethics committee (Hachinohe City Hospital, Hachinohe,
Aomori, Japan) and registered at UMIN-CTR
(UMIN000019785). The records of 63 patients who were
all the patients undergoing upper abdominal surgery
(not included laparoscopic surgery) under general
anesthesia used sevoflurane and remifentanil for the
maintenance between March 2007 and February 2012
were examined retrospectively. This study was observa-
tional, non-randomized and not controlled. The American
Society of Anesthesiologists physical status of all patients
was class 1 or 2.
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Anesthesia was induced with midazolam (0.04 mg/kg)
and remifentanil, and maintained with sevoflurane
(1–1.5%) and remifentanil. Tramadol (3.5 mg/kg)
was administered intravenously at the induction of
anesthesia and an additional 1.5 mg/kg was given
every 4 h thereafter. Patients were divided into four
groups on the basis of remifentanil dose and trama-
dol administration: group HT(+) received high-dose
remifentanil (1–1.5 μg/kg/min) with tramadol; group
HT(−) received high-dose remifentanil without tram-
adol; group LT(+) received low-dose remifentanil
(0.15–0.25 μg/kg/min) with tramadol; and group
LT(−) received low-dose remifentanil without trama-
dol. The high-dose remifentanil group (1–1.5 μg/kg/
min) was defined from the dose we have usually
administered in upper abdominal surgery. The low-
dose remifentanil group (0.15–0.25 μg/kg/min) was
defined from the empirical dose we thought to be
the minimum in upper abdominal surgery. We used
Ultiva® (remifentanil hydrochloride) as remifentanil
preparation. Intravenous tramadol was adopted for
post operating shivering in our hospital in 2010. In
this study, group LT(+) and group HT(+) were after
2011. Fentanyl, flurbiprofen (2 mg/kg, except when
it is contraindicated as asthma, intestinal ulcer and
reduced renal function) and intravenous patient con-
trolled analgesia (IV-PCA) with fentanyl, or epidural
anesthesia were used as postoperative analgesia. Flur-
biprofen was administered 30 min before completion
of surgery. Premedication was not administered. All
fluids were pre-warmed. Episodes of PAS were iden-
tified from anesthetic and medical records. In our
hospital, we have to record the occurrence of PAS as
complication if shivering occurred. Then we could
identify patients with shivering from past electronic
chart. Post-anesthetic shivering was evaluated by not
the same person, but each anesthesiologist was in charge.
The evaluation was performed within one hour after sur-
gery. Duration of surgery and anesthesia, and administra-
tion of flurbiprofen were also recorded. Core temperature
was measured in the nasopharynx. A thermometer cath-
eter (Temperature probe, Drager, USA) was placed imme-
diately after induction of anesthesia and removed at the
end of surgery by attending anesthesiologist; the difference
between the two was calculated. In the period from 2007
to 2012, we did not apply active warming for surgical
patients during anesthesia due to lack of the equipment.
Alternatively to prevent body temperature decrease, room
temperature of our operating room was maintained ap-
proximately at 25 °C as possible and an underbody warm-
ing blanket as well as a transfusion warming device were
commonly used. These efforts might not remarkably re-
duce the mean nasopharyngeal temperature of patients
during surgery.
Statistical analysis
Based on a preliminary study, power analysis (α = 0.05,
β = 0.20) indicated that fewer than 10 subjects per group
would be needed to detect a significant difference in the
incidence of PAS in the high- or low-dose remifentanil
groups. Then fifteen subjects were needed per group, to
account for potential protocol failures or dropouts. Data
are presented as median [minimum, maximum]; n de-
notes the number of patients. Data were analyzed using
the Prism 6 software package (GraphPad software, CA
USA). Fisher’ exact test and the ordinary one- or two-
way analysis of variance (ANOVA) were used for stat-
istical analyses. Holm-Sidak test, Dunn’s or Tukey’s
multiple comparison post hoc tests were performed
for Fisher’s exact test, one-way one- or two-way
ANOVA, respectively; p values <0.05 were considered
statistically significant.
Results
Patient characteristics and basic anesthetic data
There were no significant differences in mean age,
height or weight, or the ratio of men to women, between
the groups. There were also no significant differences in
mean nasopharyngeal temperature before surgery, dur-
ation of anesthesia, duration of surgery, bleeding, PONV
and flurbiprofen dose among the groups. However the
patients used epidural anesthesia as postoperative anal-
gesia were more in HT(−) group than the other groups.
Amount of fentanyl during surgery in the HT(+) group
was significantly larger than that in the HT(−) group.
Amount of Mg2+ during surgery was also higher in
HT(−) group. The dose of fentanyl of iv-PCA was 25 μg/
h as median value in all groups (Table 1).
Operative methods
Operative methods in all groups were shown (Table 2).
Post-anesthetic shivering
In the low-dose remifentanil group, the incidence of
PAS was significantly lower in the tramadol-treated
group than the group who did not receive tramadol (one
out of 16 (6.25%) compared with seven out of 15
(46.7%), respectively, p = 0.015). Similarly, the inci-
dence of PAS in the high-dose remifentanil group was
significantly lower in the tramadol-treated group than
the group who did not receive tramadol (none out of 17
(0%) compared with four out of 15 (26.7%), respect-
ively, p = 0.038). The dose of remifentanil did not appear
to influence the incidence of PAS in those treated with
tramadol (none out of 17 (0%) in the HT(+) group com-
pared with one out of 16 (6.25%) in the LT(+) group; p
= 0.48), or those not treated with tramadol (four out of
15 (26.7%) in the HT(−) group compared with seven out
of 15 (46.7%) in the LT(−) group, p = 0.45; Fig. 1).
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Perioperative change in nasopharyngeal temperature
Mean nasopharyngeal temperature at the end of surgery
was significantly higher in the HT(−) group than the
HT(+) group (36.4 ± 0.4 °C compared with 35.6 ± 0.6 °C,
respectively; p =0.008). Similarly, the perioperative
temperature change; the temperature before surgery
minus that after surgery; was significantly greater in the
HT(+) than the HT(−) group (0.4 ± 0.5 °C compared
with −0.2 ± 0.3 °C, respectively; p =0.040). There was no
difference in mean nasopharyngeal temperature after
surgery between the LT(+) and LT(−) groups (35.6 ± 0.9 °C
compared with 36.1 ± 0.5 °C, respectively; p = 0.18). There
was also no difference in perioperative temperature change
in the LT(+) than the LT(−) group (0.6 ± 0.9 °C compared
with 0.0 ± 0.5 °C, respectively; p = 0.06).
Discussion
We found that tramadol significantly decreased the inci-
dence of PAS after remifentanil anesthesia, regardless of
Table 1 Participants’ demographic and clinical characteristics
LT(+) LT(−) HT(+) HT(−)

























































































15/16 10/15 15/17 9/15
*PONV 0/16 1/15 0/17 0/15
*The patients administrated Additional analgesics after surgery 2/16 3/15 6/17 5/15
*The case using iv-PCA 15/16 12/15 17/17# 7/15
*The case using epidural anesthesia 0/16 3/15 0/17# 7/15
Number 16 15 17 15
Data are presented as median [minimum, maximum]. One-way analysis of variance with Dunn’s multiple comparison test or Fisher’s exact test (*) with Holm-sidak
test was used to compare each group with every other. Fisher’s exact test (*) was used to compare
Abbreviation: LT(+) low-dose remifentanil group treated with tramadol, LT(−) low-dose remifentanil not treated with tramadol, HT(+) high-dose remifentanil group
treated with tramadol, HT(−) high-dose remifentanil group not treated with tramadol, n.s. not significant, PONV postoperative nausea and vomiting
#p < 0.05 versus HT(−) group
Table 2 Number of Undertaken surgery in each group
LT(+) LT(−) HT(+) HT(−) all
Distal Gastrectomy 7 8 7 7 29
Total Gastrectomy 6 5 6 3 20
Hepatectomy 1 1 3 1 6
Pancreaticoduodenectomy 1 1 0 2 4
Distal Pancreatectomy 1 0 0 0 1
Pancreaticogastrostomy 0 0 1 0 1
Subtotal Gastrectomy 0 0 0 1 1
Gastrojejunostomy 0 0 0 1 1
total 16 15 17 15 62
Operative methods undertaken in each group
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the dose of remifentanil (Fig. 1a). Tramadol inhibits
neuronal reuptake of norepinephrine and 5-
hydroxytryptamine, and activates μ-opioid receptors,
with minimal activity at κ- or σ-receptors [17]. Tramadol
also reportedly inhibits the N-methyl-D-aspartic acid
(NMDA) receptor at clinically relevant concentrations
[18]. Pethidine is widely used to prevent PAS, while
tramadol has also been reported to be effective [19]. Seifi
et al. also reported that pethidine 0.5 mg/kg is as effect-
ive as tramadol 1 mg/kg for PAS during the first 15 min
after injection, while tramadol is associated with less side
effects [20]. Heid et al. reported that administration of
2 mg/kg tramadol reduced the incidence and extent of
PAS after lumbar disc surgery under remifentanil-
isoflurane general anesthesia [16]. Mohta et al. also re-
ported that tramadol 2 mg/kg provided an effective
combination of anti-PAS activity and analgesia without
excessive sedation [8]. Moreover, Heidari et al. found
that premedication with oral tramadol reduced the se-
verity of PAS [9]. In preliminary study, we also originally
administered tramadol 2 mg/kg, but PAS still occasion-
ally occurred. However shivering hardly occurred after
we administered tramadol 200 mg. Then we adminis-
tered tramadol 200 mg at induction of anesthesia, equat-
ing to approximately 3 mg/kg, followed by 100 mg every
4 h. The interval of 4 h was estimated from the bio-
logical half-time of tramadol, which is in the region of
5 h when administered orally. Kose et al. have reported
that ketamine was effective for PAS [21]. Ketamine is a
competitive antagonist at the NMDA receptor, suggest-
ing that the anti-shivering effect of tramadol might be
mediated by the NMDA receptor.
In this study, mean nasopharyngeal temperatures were
not markedly reduced in the non-tramadol treatment
group (HT(−); from 36.3 ± 0.37 to 36.4 ± 0.4, LT(−); from
36.1 ± 0.29 to 36.1 ± 0.5). This reason is that non-
shivering thermogenesis might be occurred. Additionally
perioperative nasopharyngeal temperature fell signifi-
cantly more in the HT(+) and LT(+) groups than the
HT(−) and LT(−) groups. Tramadol may suppress the
central nervous system temperature regulatory center
causing dissipation of heat from the core to the periphery,
while maintaining core temperature above the threshold
for shivering. This is an interesting observation, as low
core temperature at the time of completion of surgery is
generally considered to pose a high risk for shivering.
We focused on shivering after remifentanil anesthesia.
Ultiva® contains 15 mg glycine and hydrochloric acid.
Glycine is required for the activation of the NMDA re-
ceptor [22]. Assuming that the NMDA receptor is in-
volved in shivering, the PAS after remifentanil anesthesia
might be a consequence of activation of NMDA recep-
tors by the glycine contained in the drug preparation.
Thus, tramadol might effectively suppress PAS by inhi-
biting the NMDA receptor. Short-acting opioids may
cause acute opioid tolerance and hyperalgesia [23];
Fig. 1 The effects of tramadol or remifentanil dose on the incidence of postoperative shivering: (a) the low-dose remifentanil group (n = 31) included
16 who were treated with tramadol treatment [LT(+)] and 15 who were not [LT(−)] and (b) the high-dose remifentanil group (n = 32) included 17
treated with tramadol [HT(+)] and 15 who were not [HT(−)]; (c) the tramadol treatment group (n = 33) included 17 administered high-dose remifentanil
and 16 who were administered low-dose remifentanil, while (d) the group not administered tramadol group (n = 30) included 15 who received
high-dose remifentanil and 15 who received low-dose remifentanil. The white portion represents those patients who did not shiver postoperatively,
and the black portion those who experienced postoperative shivering. Fisher’s exact test was used for statistical analyses
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indeed Nakasuji et al. suggested that PAS was a conse-
quence of opioid withdrawal caused by acute tolerance
[7]. Wu et al. reported that NMDA receptor antagonists
did not significantly reduce the incidence of PAS [24];
however, their cohort included patients undergoing sep-
torhinoplasty or thyroidectomy, after which the inci-
dence of PAS is recognized to be low.
In this study, we obtained interesting results regarding
nasopharyngeal temperature. Administration of a high
concentration of remifentanil caused a greater but non-
significant increase of nasopharyngeal temperature com-
pared with the low concentration (Fig. 2a, HT(−) vs.
LT(−), p = 0.069). Moreover, the use of tramadol from
the start of Ultiva® administration decreased nasopharyn-
geal temperature in the high concentration of remifenta-
nil group (Fig. 2a). Given these results, we propose four
possible explanations. First, administration of Ultiva®
might increase core temperature, while shivering might
not occur during administration. Second, the hyperther-
mic effect of Ultiva® might be related to stimulation of
the NMDA receptor by glycine in Ultiva®. Third, shiver-
ing might not occur during Ultiva® administration
because remifentanil in Ultiva® or other anesthetics
administered simultaneously suppressed shivering.
Fourth, shivering after remifentanil anesthesia might be
a result of the sudden decrease of the ability of remifen-
tanil to suppress shivering. We believe there may be
complex thermoregulatory mechanisms via the NMDA
receptor and opioid receptor (ex-vivo), which may ac-
count for the occurrence of shivering (in-vivo).
In this study, while there were no differences in naso-
pharyngeal temperature between the LT(−) group and
LT(+) group at the end of surgery, it was significantly
higher in the HT(−) group compared with the HT(+)
group. The reason might be that the low-dose glycine
(low-dose Ultiva®) did not sufficiently activate NMDA
receptors in the low remifentanil concentration groups
LT(−) group. The lowering effect on body temperature
via suppression of the thermoregulatory center by tram-
adol might be therefore too small to exceed the signifi-
cance threshold in the LT(+) group. By contrast, the
high-dose glycine might sufficiently activate NMDA
receptors such that a strong hyperthermic response oc-
curred in the HT(−) group, and the body temperature-
lowering effect of tramadol might exceed the threshold
in the HT(+) group. Further research is required to fully
understand the relationship between PAS and the
NMDA receptor.
We found no relationship between the dose of remi-
fentanil and the incidence of PAS. Nakasuji et al.
reported that the incidence of PAS was higher after
high-dose remifentanil (0.25 μg/kg/min) than a low-dose
regime (0.1 μg/kg/min) [7]. We defined low dose as
0.1–0.25 μg/kg/min and high dose as 1–1.5 μg/kg/
min. Differences between our findings and those of past
studies might be a consequence of different definitions.
Limitations
This study has some limitations. First, its design was
retrospective and patients were not randomized. In
HT(−) group, the number of patients used epidural
anesthesia was larger than another group (LT(−): 3 out
of 15, HT(−): 7 out of 15, LT(+): 0 out of 16, HT(+) 0
out of 17). Moreover, the amount of fentanyl adminis-
tered during surgery and the estimated effect site con-
centration of fentanyl at end of surgery were not
standardized. In this study, the incidence of PAS was sig-
nificantly lower in the patients who used epidural
anesthesia than the patients who used iv-PCA (none out
of 7 (0%) compared with four out of 7 (57.1%), respect-
ively; p = 0.018, not shown) in HT(−) group. Therefore,
epidural anesthesia may be superior to fentanyl adminis-
tration in PAS. Second, we studied only those undergo-
ing upper abdominal surgery and the duration of surgery
varied widely, likely resulting in wide variation in surgi-
cal stress that might have influenced the incidence of
PAS. Third, we assessed only whether shivering occurred
Fig. 2 Postoperative nasopharyngeal temperature and perioperative
nasopharyngeal temperature change: (a) nasopharyngeal temperature
after surgery and (b) change from before surgery to after surgery in
the high-dose remifentanil group. Ordinary two-way analysis of
variance (ANOVA) was used for statistical analyses. Tukey’s multiple
comparison post hoc tests were performed for two-way ANOVA.
The upper, middle and lower bars indicate maximum, median and
minimum value each
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or not. Assessing the extent and duration of shivering
might further illuminate the effect of tramadol. Ideally, a
trained observer should record shivering in a reliable
and standardized manner, but we could not. Fourth, we
did not measure peripheral temperature; the central-
peripheral temperature difference might have been in-
fluenced by tramadol. Finally, we did not standardize
flurbiprofen or fentanyl administration. Although flur-
biprofen did not influence the incidence of PAS in
our study, there was possibility that non-steroidal
anti-inflammatory drugs might have effects on the
distribution of body heat from the core to the periphery.
The small sample size per group (15–17 patients) might
not provide effects of flubiprofen on shivering.
Further prospective studies are needed to examine the
effects of tramadol on PAS.
Conclusion
Post-anesthetic shivering appeared to occur independ-
ently of remifentanil concentration. Administration of
tramadol significantly reduced the incidence of PAS
independently of remifentanil concentration. Tramadol
may be a useful means of preventing PAS.
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PCA: Intravenous patient controlled analgesia; LT(−): low-dose remifentanil
(0.15–0.25 μg/kg/min) without tramadol; LT(+): Low-dose remifentanil
(0.15–0.25 μg/kg/min) with tramadol group; NMDA: N-methyl-D-aspartic
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